Abstract
Ten years elapsed since the discovery by Sanofi of SR141716A the first selective CB1 cannabinoid receptor antagonist. Shortly after, Sanofi also reported the synthesis of the first selective CB2 cannabinoid receptor antagonist, SR144528. Since these two milestones in the cannabinoid field, many other compounds, more or less related to the Sanofi compounds, or based on a completely different scaffold appeared. Several of these compounds are currently involved in clinical trials for diseases such as obesity, nicotine and alcohol addictions, or allergies. Further, the cannabinoid receptors knock-out mice production strengthened the hypothesis of the existence of several other “cannabinoid” receptors for which the first antagonists begin to appear. The large amount of patents taken by many different pharmaceutical companies prove, if necessary, the great therapeutic potential expected for the cannabinoid receptors antagonists.
Keywords: cannabinoid, antagonism, inverse agonism, rimonabant, sr, slv
Current Medicinal Chemistry
Title: Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors
Volume: 12 Issue: 12
Author(s): G. G. Muccioli and D. M. Lambert
Affiliation:
Keywords: cannabinoid, antagonism, inverse agonism, rimonabant, sr, slv
Abstract: Ten years elapsed since the discovery by Sanofi of SR141716A the first selective CB1 cannabinoid receptor antagonist. Shortly after, Sanofi also reported the synthesis of the first selective CB2 cannabinoid receptor antagonist, SR144528. Since these two milestones in the cannabinoid field, many other compounds, more or less related to the Sanofi compounds, or based on a completely different scaffold appeared. Several of these compounds are currently involved in clinical trials for diseases such as obesity, nicotine and alcohol addictions, or allergies. Further, the cannabinoid receptors knock-out mice production strengthened the hypothesis of the existence of several other “cannabinoid” receptors for which the first antagonists begin to appear. The large amount of patents taken by many different pharmaceutical companies prove, if necessary, the great therapeutic potential expected for the cannabinoid receptors antagonists.
Export Options
About this article
Cite this article as:
Muccioli G. G. and Lambert M. D., Current Knowledge on the Antagonists and Inverse Agonists of Cannabinoid Receptors, Current Medicinal Chemistry 2005; 12 (12) . https://dx.doi.org/10.2174/0929867054020891
DOI https://dx.doi.org/10.2174/0929867054020891 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Industrial Production of the Cell Protectant Ectoine: Protection Mechanisms, Processes, and Products
Current Biotechnology Synthesis and Screening of Substituted Thiosemicarbazone Derivatives: An Approach towards Novel Anticonvulsant Search
Central Nervous System Agents in Medicinal Chemistry The Addiction Potential of Hyperpalatable Foods
Current Drug Abuse Reviews Serotonergic Modulation of Spinal Sensory Circuits
Current Topics in Medicinal Chemistry Mitogen Activated Protein (MAP) Kinases: Development of ATP and Non- ATP Dependent Inhibitors
Medicinal Chemistry Schwann Cell Transplantation for CNS Repair
Current Medicinal Chemistry Elevated C-reactive Protein Levels in Women with Bipolar Disorder may be Explained by a History of Childhood Trauma, Especially Sexual Abuse, Body Mass Index and Age
CNS & Neurological Disorders - Drug Targets Conceptualizing the Multifaceted Determinants of the Duration of Untreated Psychosis
Current Psychiatry Reviews Brain Inflammation, Cholesterol, and Glutamate as Interconnected Participants in the Pathology of Alzheimers Disease
Current Pharmaceutical Design Cerebral Angiogenesis and Expression of Angiogenic Factors in Aging Rats after Exercise
Current Neurovascular Research Editorial [Hot Topic: Pharmacogenomics: Achievements, Challenges and Prospects, for Patients, Pharmaceutical Industries and Healthcare Systems (Guest Editor: Despina Sanoudou)]
Current Pharmaceutical Design How Much Value Would a Treatment for Alzheimer’s Disease Offer? Cost-Effectiveness Thresholds for Pricing a Disease-Modifying Therapy
Current Alzheimer Research Optimizing ADAS-Cog Worksheets: A Survey of Clinical Trial Rater s’ Perceptions
Current Alzheimer Research Early Diagnosis of Alzheimers Disease: Is MCI Too Late?
Current Alzheimer Research Mechanisms of Action and Chemical-Biological Interactions Between Ozone and Body Compartments: A Critical Appraisal of the Different Administration Routes
Current Drug Therapy Editorial (Thematic Issue: Pharmacogenetics and Molecular Medicine: “So Close and Yet So Far”)
Current Molecular Medicine Relationship of Neurofilament Light (NfL) and Cognitive Performance in a Sample of Mexican Americans with Normal Cognition, Mild Cognitive Impairment and Dementia
Current Alzheimer Research Patterns of Adverse Drug Reaction in the Medical Wards of a Teaching Hospital: A Prospective Observational Cohort Study
Current Drug Safety Role of Hydrogen Sulfide and Polysulfides in Neurological Diseases: Focus on Protein S-Persulfidation
Current Neuropharmacology Potential Effects of Cannabidiol as a Wake-Promoting Agent
Current Neuropharmacology